Regulatory Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Big Molecule WatchOn May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Big Molecule Watch On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Read full story Post navigation Previous: SCOTUS backs generic firm Hikma in skinny label disputeNext: Pfizer signs licence agreement with Chai for AI drug discovery Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026